Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3833294 | 1.00 | MEN1 (0.43) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3828847 | 0.88 | TRPV1 (0.48) | — | |
| SCHEMBL4677159 | 0.88 | MEN1 (0.46) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL4641458 | 0.88 | MEN1 (0.46) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3828863 | 0.88 | TRPV1 (0.48) | — | |
| SCHEMBL3826666 | 0.86 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL3826916 | 0.86 | MEN1 (0.42) | MEN1KMT2A | |
| SCHEMBL3825869 | 0.85 | TRPV1 (0.41) | — | |
| SCHEMBL3825837 | 0.85 | TRPV1 (0.41) | — | |
| SCHEMBL4640597 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858865-B1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2009-09-16 | — | — | EP | claimed |
| US-7566739-B2 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER INC. (US) | 2009-07-28 | — | — | US | claimed |
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER, INC. | 2006-09-14 | — | — | US | claimed |
| EP-1858865-B1 | SUBSTITUTED N-SULFONYLAMINOPHENYLETHYL-2-PHENOXY ACETAMIDE COMPOUNDS | PFIZER (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7566739-B2 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | CNR1, HVCN1, AVPR1A | MEN1 1322/4885KMT2A 2669/4885GRIN1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.